Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Primary Myelofibrosis 13Myeloproliferative Disorders 9Leukemia, Myeloid, Acute 8Thrombocythemia, Essential 6Polycythemia Vera 6Myelodysplastic Syndromes 5Leukemia 5Recurrence 3Neoplasms 3Lymphoma, T-Cell 3Graft vs Host Disease 3Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Uveal Melanoma 1Thalassemia 1Targeted Therapy 1Prostatic Neoplasms 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neoplasms by Histologic Type 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Cyclophosphamide 18fludarabine phosphate 12pembrolizumab 11Nivolumab 11Brentuximab Vedotin 11Mycophenolic Acid 10Doxorubicin 10fludarabine 9Dacarbazine 9Whole-Body Irradiation 8Etoposide 8Vinblastine 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Filgrastim 7Cyclosporine 7Granulocyte Colony-Stimulating Factor 6Sirolimus 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Gemcitabine 5Busulfan 5Tacrolimus 4pegfilgrastim 3Vinorelbine 3Stem Cell Transplantation 3Rituximab 3Radiation 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × ruxolitinib × 90 days × Clear all
NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Big Ten Cancer Research Consortium

Phase 1/2 Recruiting
54 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡